Skip to content
  • English
  • Business
  • Entertainment
  • National
  • Lifestyle
  • Education
Daily News India

Daily News India

Just another WordPress site

  • English
  • Business
  • Entertainment
  • National
  • Lifestyle
  • Education
  • Toggle search form
  • Entrepreneur Asif Bezalel, aka Deduction, makes massive noise in the gaming world Business
  • Here’s why ‘Hyderabad-Vijayawada Highway’ is the ‘Next Gachibowli’! Business
  • BigBloc’s Starbigbloc Building Material To install 800 KW solar rooftop power project at Kheda Unit Business
  • WireMonster’s Co-Founder Jitan Reveals What Inspires Him to Achieve His Business Dreams Business
  • Palladian Partners Embarks on Ambitious Expansion plan, Targets 30 New Cities in India Business
  • Embrace Handloom Heritage at the Aatmanirbhar Bharat Utsav in Chandigarh Lifestyle
  • Farewell to a Legend: Colonel Prem Nath Khera is No More National
  • Mahindra Launches ‘THE’ SUV: Thar ROXX Lifestyle

Optimus PharmaSeeks Emergency Approval to Conduct Phase 3 Clinical Trial of Molnupiravir for COVID-19 in India

Posted on April 27, 2021 By

Hyderabad [Telangana], April 27: Dr. D. Srinivas Reddy, Chairman, and CEO of Optimus Pharma announced that they have filed for seeking emergency approval for Phase 3 Clinical Trial from the Drugs Controller General of India. Once the approval is granted for Phase 3 Clinical Trial, we would be extensively accelerating the manufacturing of our in-house developed generic version of Molnupiravir for making it available in the Indian market as soon as possible. Optimus Pharma is committed to halting the pandemic across the nation and ensuring immediate relief to all those who have been infected with the highly virulent SARS-CoV-2.

Optimus Pharma is pleased to announce the development of oral Molnupiravir on the fast lane. Optimus Pharma is becoming a key player in the fight against the COVID-19 pandemic in India has already achieved very high production levels of Favipiravir one of our flagship drugs for COVID-19 infection. In a bid to develop and diversify our anti-viral portfolio especially against SARS-CoV-2, we are here with yet another promising drug to compensate for the lack of antiviral drugs in the market further diversifying our antivirals portfolio. In hindsight of the raging second wave, Molnupiravir has been developed for non-hospitalized mild to moderate infections of SARS-CoV-2. Optimus Pharma is aggressively pushing for achieving scalability for 800mg dose of the drug.

Our available pre-clinical data on Molnupiravir already demonstrated that there were no adverse clinical signs and mortality observed in any of the treatment groups, as compared to the control group of animals with high efficacy and thereby effectively neutralizing virulence of the SARS-CoV-2 virus in the test group as compared to control group.

The drug is effective against a variety of viruses that use an RNA-dependent RNA polymerase (RdRp), as is the case with SARS-CoV-2 which is directly responsible for the transcription of Viral m-RNA of the virus in the infected subject. Early in vitro tests of Molnupiravir on SARS-CoV-2 revealed a steady decrease in virus output that was proportional to the dose of Molnupiravir used. Since the RdRp of SARS-CoV-2 and SARS-CoV, which the drug was designed to treat, has 99.1% nucleotide similarity hence, this was possible. Repeated drug exposure quickly neutralized virus populations, ensuring that none of the random mutations mediate drug resistance. As the drug is introduced in higher amounts, the titer levels and genome output of SARS-CoV-2 decrease exponentially.

It has been observed that Molnupiravir is only marginally successful in preventing extreme SARS-CoV-2 infection that is severe cases of the infection. This might have been the reason for their withdrawal and continue the trial only with non-hospitalized patients that are subjects with mild to moderate infection. We aim to do the same and establish its efficacy in the same treatment group.

Phase 2 Clinical Trial study on enrolled 202 non-hospitalized adults is already made available by the innovator of the molecule. Virological analysis was characterized by a marked decrease in positive viral culture in subjects who received Molnupiravir (all doses) relative to placebo – at day 5: 0% (0/47) for Molnupiravir and 24% (6/25) for placebo. Furthermore, the secondary objective for a faster decrease in infectious virus among people with early COVID-19 who were treated with Molnupiravir is encouraging and Phase 3 Clinical Trials are warranted for checking the efficacy of the molecule across demographics, particularly as the SARS-CoV-2 virus continues to spread and evolve globally.

Unlike the current drugs being administered intravenously, Molnupiravir is administered orally. This makes it a promising drug to halt the disease progression in the early stages as well as mount a powerful response against moderate infection levels. The fact that this molecule can be consumed as an orally administered drug in the form of an 800mg capsule renders a maverick advantage to achieve scalability in terms of upscaling from gm scale to multi-ton levels in a short time frame, thereby ensuring availability in the Indian market at a comparatively exponential scale. In vitro assays indicate that it is significantly more effective than the drugs being used currently, and the safety profile appears to be satisfactory.

English, Health Tags:DrDSrinivasReddy, OptimusPharmaSeeks, PNN

Post navigation

Previous Post: Indian Leadership Academy – A one-stop destination for all your training and coaching needs in Leadership and mindful learning
Next Post: XERTZ launches first-ever true wireless stereo technology-based Audio-frame glasses and sunglasses for the Indian market

Related Posts

  • The Hidden Dangers of Modern Lifestyle Habits: A Growing Cancer Concern Health
  • Public Affairs Forum of India (PAFI) announces New Office Bearers for 2021-22. Dr. Subho Ray to be the new President English
  • Awstro is Taking New Steps to Add New Categories & Development A
  • Layers, A Hair Transplant Clinic in Hyderabad, Implements Direct Hair Implantation (DHI) To Help Its Clients Tackle Premature Baldness Health
  • Throttle Shrottle Extends Legacy With Launch Of Leopard Trail Cafe and Stay In The Foothills Of Aravalli Range Business
  • My Safety Card assures protection you against all bacteria and Viruses including Covid19 English

Recent Posts

  • Emerald Finance Reports Stellar 138% YoY Growth in Standalone Net Profit for Q1 FY26
  • Trehan Media and Adio Brand Solutions Win Co-Branding Rights for 14 Iconic Delhi Metro Stations: A New Chapter in Urban Brand Engagement
  • MetaMix Technologies Revolutionizes Medical Education in India with anatomyXR — A Mixed Reality Leap Forward
  • Aayush Wellness Launches Brain Fuel Capsules
  • India’s AI Future Begins Here: Scaler School of Technology’s New-Age Engineering Blueprint

Recent Comments

  • Unknown on Participants Reap Rewards in Wellman’s 8-Week Digital Campaign: IPL Tickets, Autographed Virat Kohli Merchandise, and More!
  • Eye Opener for Giant Pharma Bulls!!! Business
  • BSM Tech: A Young Entrepreneur’s Journey into Wearable Tech Business
  • Inspiring story of Suresh Gurwani: a multi-talented entrepreneur & founder of Sarvatm Digital Media Services Business
  • VimoSEWA celebrates 30 years of insuring women workers in the informal sector Business
  • ‘Uniform and Sportswear Expo 2023’ To Be Held During 23rd To 25th November, 2023 At Nehru Centre, Mumbai Business
  • Hafele’s Kabi-Net Digital Locks Business
  • Cosmetico Labs introduce India’s first ‘Beauty Incubator’ Business
  • Legendary Singer Kumar Sanu Collaborates with Sandy Kaur for a heartfelt track “Tum Khaffa Ho gaye” Entertainment

Copyright © 2025 Daily News India.

Powered by PressBook News WordPress theme